Feature | December 15, 2014

St. Joseph's Children's Hospital Implants 50th Pulmonary Valve Without Open-Heart Surgery

Facility is highest-volume Melody valve implanting center in Florida, one of the busiest in the United States

December 15, 2014 — Doctors at St. Joseph’s Children’s Hospital of Tampa implanted a Melody transcatheter pulmonary valve in a 13-year-old patient in October, marking the 50th time the hospital has given the device to a patient.

Thirteen-year-old Cyrus Yarley was born with multiple heart defects and underwent open-heart surgery at just 1 week old then again at age 8. His mother, Valorie Daniels, knew the day would come when Cyrus would need to have his pulmonary valve replaced, and had anticipated another open-heart surgery for the past five years. Use of the Melody valve, however, precluded the need for an additional incision. After inserting a catheter into a vein in the upper leg, pediatric cardiologist Jeremy Ringewald, M.D., guided the Melody valve up to Cyrus' heart and replaced his current dysfunctional pulmonary valve

The Melody valve from Medtronic replaces narrow or leaky pulmonary valve conduits in children or adults who have previously undergone congenital heart surgery. St. Joseph's Children's Hospital is the highest-volume Melody valve implanting center in Florida and one of the busiest in the United States.

"Children born with blocked or leaky heart valves usually undergo multiple open-heart surgeries before reaching adulthood to replace conduits that have worn out or that they have outgrown," said Ringewald. "This groundbreaking technology can markedly prolong the time between surgeries for many patients, with the goal of maximizing heart health and minimizing invasiveness."

According to Ringewald, the Melody valve procedure is typically performed under general anesthesia in less than four hours. Unlike open-heart surgical procedures, where the hospital stay is approximately a week, patients are usually discharged from the hospital within 24 hours. 

While Melody valve therapy cannot be used in all cases of abnormal pulmonary valve function, it can give doctors an alternative to repeated traditional open-heart procedures, offering children and adults who may not be able to tolerate another open-heart surgery hope for the future.

For more information: www.medtronic.com

Related Content

A sample of the transcatheter mitral valve replacement (TMVR) devices in development or clinical trials.

A sample of the transcatheter mitral valve replacement (TMVR) devices in development or clinical trials.

Feature | Heart Valve Technology | November 27, 2019 | Saipriya Iyer
The overwhelming success story for transcatheter aortic valve replacement (TAVR) moving from a science project to bec
A key slide from the TRILUMINATE study one-year results showing the improvement in tricuspid regurgitation from basement with treatment using the transcatheter TriClip device.

A key slide from the TRILUMINATE study one-year results showing the improvement in tricuspid regurgitation from basement with treatment using the transcatheter TriClip device.

News | Heart Valve Technology | November 26, 2019 | Dave Fornell, Editor
November 26, 2019 — The preliminary one-year results of the TRILUMINATE Pivotal Study for Abbott's TriClip device, a
 Retired National Football League (NFL) star Ed White, the former Chargers guard and four-time Pro Bowler, waited until the FDA approved TAVR for low-risk patients like himself to avoid open-heart surgery.

Retired National Football League (NFL) star Ed White, the former Chargers guard and four-time Pro Bowler, waited until the FDA approved TAVR for low-risk patients like himself to avoid open-heart surgery.

Feature | Heart Valve Technology | October 29, 2019
October 29, 2019 — When Scripps cardiologists discovered early in 2019 that retired National Football League (NFL) gr
A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography. Study Finds Sustained Benefit for TAVR vs. SAVR at One Year. #TCT2019 #TCT19

A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography.

News | Heart Valve Technology | October 04, 2019
October 4, 2019 – A new analysis of the PARTNER 3 Trial data found a modest, but significant, improvement in one-year
Five-year results from the PARTNER 2A Trial found patients with severe aortic stenosis (AS) and intermediate surgical risk who underwent Sapien 3 transcatheter aortic valve replacement (TAVR) had similar rates of death and disabling stroke compared to those who had surgical aortic valve replacement (SAVR). However, TAVR using a transthoracic approach had poorer outcomes compared to SAVR. #TCT2019
News | Heart Valve Technology | October 03, 2019
October 3, 2019 – Five-year results from the PARTNER 2A Trial found patients with severe aortic stenosis (AS) and int
The Boston Scientiofic Acurate Neo TAVR valve did not meet non-inferiority to the Sapien 3 valve in patients with severe aortic stenosis. #TAVR #TCT2019
News | Heart Valve Technology | October 02, 2019
October 2, 2019 – The first randomized trial to compare the safety and efficacy of the new Boston Scientific Acurate
The Portico FDA investigational device exemption (IDE) study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems. #TAVR #TCT2019
News | Heart Valve Technology | October 02, 2019
October 2, 2019 – The Abbott Portico FDA investigational device exemption (IDE) study found that 30-day safety and on
Medtronic Launches Evolut Pro+ TAVR System
Technology | Heart Valve Technology | September 24, 2019
Medtronic announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Evolut Pro+ transcatheter...
Overlay Init